Detalhe da pesquisa
1.
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 61(6): 783-8, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22109700
2.
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.
Cancer Immunol Immunother
; 61(6): 771-82, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22057678
3.
Performance characteristics of EUS-FNA biopsy for adrenal lesions: A meta-analysis.
Endosc Ultrasound
; 8(3): 180-187, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30880721
4.
Variations in Screening Adenoma Detection Rate by Specialty of Physicians in a Predominately African American Population.
Cureus
; 11(10): e6003, 2019 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31807390
5.
Immunopharmacology of thymosin alpha1 and cytokine synergy.
Ann N Y Acad Sci
; 1112: 235-44, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17567942
6.
Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C.
Hepat Med
; 9: 13-16, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28356778
7.
Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
J Interferon Cytokine Res
; 36(5): 291-301, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26653678
8.
T cell targeted immune enhancement yields effective T cell adjuvants.
Int Immunopharmacol
; 3(8): 1205-15, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12860176
9.
Overlapping molecular signaling of IRX-2 and Ta1 resulting in synergistic biological activity.
Expert Opin Biol Ther
; 18(sup1): 85-88, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29792763
10.
Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen.
Cancers (Basel)
; 3(4): 3991-4009, 2011 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24213121
11.
Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.
Ann N Y Acad Sci
; 1194: 162-8, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20536465
12.
IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Vaccine
; 28(43): 7054-62, 2010 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20708999